Patents Examined by Kagnew H. Gebreyesus
  • Patent number: 11154064
    Abstract: The present invention relates to a composition comprising a) recombinant exosporium-producing Bacillus cells that express a fusion protein comprising: (i) at least one plant growth stimulating protein or peptide and (ii) a targeting sequence that localizes the fusion protein to the exosporium of the Bacillus cells; and b) at least one further biological control agent selected from particular microorganisms disclosed herein and/or a mutant of a specific strain of a microorganism disclosed herein having all identifying characteristics of the respective strain, and/or at least one metabolite produced by the respective strain, and/or at least one metabolite produced by the respective strain that exhibits activity against insects, mites, nematodes and/or phytopathogens in a synergistically effective amount. Furthermore, the present invention relates to the use of this composition as well as a method for enhancing plant growth, promoting plant health, and/or reducing overall damage of plants and plant parts.
    Type: Grant
    Filed: September 17, 2015
    Date of Patent: October 26, 2021
    Assignees: Bayer CropScience LP, Spogen Biotech Inc.
    Inventors: Damian Curtis, Brian Thompson
  • Patent number: 11155804
    Abstract: Composition comprising purified recombinant selenoproteins, such an antibodies and enzymes, are provided. Method of producing such recombinant polypeptides and bacterial strains for the same are likewise provided.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: October 26, 2021
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Andrew D. Ellington, Ross Thyer
  • Patent number: 11155799
    Abstract: The present invention provides methods, compositions and articles of manufacture useful for the prophylactic and therapeutic amelioration and treatment of gram-positive bacteria, including Streptococcus and Staphylococcus, and related conditions. The invention provides compositions and methods incorporating and utilizing Streptococcus suis derived bacteriophage lysins, particularly PlySs2 and/or PlySs1 lytic enzymes and variants thereof, including truncations thereof. Methods for treatment of humans are provided.
    Type: Grant
    Filed: September 5, 2019
    Date of Patent: October 26, 2021
    Assignee: THE ROCKEFELLER UNIVERSITY
    Inventors: Vincent A. Fischetti, Jonathan Schmitz, Daniel Gilmer, Chad Euler
  • Patent number: 11149092
    Abstract: Receptor protein kinases (RPTKs) transmit extracellular signals across the plasma membrane to cytosolic proteins, stimulating formation of complexes that regulate key cellular functions. Over 5 half of the known tyrosine kinases are implicated in human cancers and are therefore highly promising drug targets. A large-scale loss-of-function analysis of tyrosine kinases using RNA interference in the clinically relevant Erb-B2 positive, BT474 breast cancer cell line showed that Bruton's tyrosine kinase (BTK), a cytosolic, non-receptor tyrosine kinase that has been extensively studied for its role in B cell development, is required, in altered form, for BT474 10 breast cancer survival. This alternative form contains an amino-terminal extension that is also present in tumorigenic breast cells at significantly higher levels than in normal breast cells.
    Type: Grant
    Filed: May 1, 2017
    Date of Patent: October 19, 2021
    Assignee: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
    Inventors: Douglas S. Conklin, Cheryl Eifert, Antonis Kourtidis, Xianhui Wang, Leila Kokabee
  • Patent number: 11142749
    Abstract: The present invention is related to a trehalose phosphorylase comprising an amino acid sequence, wherein the amino acid sequence of the trehalose phosphorylase is at least 80% identical to and/or at least 80% homologous to an amino acid sequence of SEQ ID NO: 1, wherein the amino acid sequence of the trehalose phosphorylase comprises an amino acid substitution at one or more amino acid positions, wherein the one or more amino acid positions is/are selected from the group consisting of amino acid positions of SEQ ID NO: 1 712, 383, 10, 114, 118, 192, 197, 220, 225, 304, 306, 318, 323, 339, 349, 357, 459, 476, 481, 484, 487, 488, 506, 511, 526, 530, 532, 533, 537, 550, 556, 564, 590, 649, 667, 703 and 705.
    Type: Grant
    Filed: November 28, 2017
    Date of Patent: October 12, 2021
    Assignees: NEW MATTERHORN, LLC, c-LEcta GmbH
    Inventors: Birgit Brucher, Andreas Vogel
  • Patent number: 11142777
    Abstract: The present invention relates to a method for preparing a mutant strain having high producibility of phytoene and a mutant strain prepared thereby. More particularly, a Deinococcus radiodurans mutant strain, prepared by the method of the present invention, having high producibility of phytoene, does not retain an artificial antibiotic-resistant gene, although constructed by introducing a metabolism engineering method, and has high producibility of phytoene. Thus, the mutant strain prepared according to the method can find useful applications in the mass production of phytoene.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: October 12, 2021
    Assignee: University of Seoul Industry Cooperation Foundation
    Inventors: Yong Jun Choi, Sun Wook Jeong, Jua Kim, Eunkyung Hong, Kwang Jin Cho
  • Patent number: 11136571
    Abstract: The present invention provides engineered phenylalanine ammonia-lyase (PAL) polypeptides and compositions thereof, as well as polynucleotides encoding the engineered phenylalanine ammonia-lyase (PAL) polypeptides.
    Type: Grant
    Filed: October 14, 2019
    Date of Patent: October 5, 2021
    Assignee: Codexis, Inc.
    Inventors: Gjalt W. Huisman, Nicholas J. Agard, Benjamin Mijts, Jonathan Vroom, Xiyun Zhang
  • Patent number: 11136601
    Abstract: The present disclosure relates to a genetically modified microbial cell that includes a genetic modification resulting in the expression of a vanillate demethylase, where the microbial cell is capable of metabolizing at least one S-lignin decomposition molecule including at least one of syringate and/or 3-O-methyl gallate, and the genetically modified microbial cell is capable of producing gallate. In some embodiments of the present disclosure, the vanillate demethylase may include VanAB.
    Type: Grant
    Filed: August 2, 2019
    Date of Patent: October 5, 2021
    Assignee: Alliance for Sustainable Energy, LLC
    Inventors: Gregg Tyler Beckham, Christopher W. Johnson, Sandra Fabienne Notonier
  • Patent number: 11136604
    Abstract: The present invention relates to a method for producing chiral ?-nitro alcohol compounds. The invention relates in particular to an (R)-selective cupin-nitroaldolase, which enantioselectively can catalyze the Henry reaction, wherein an aldehyde or ketone compound is converted to the corresponding ?-nitro alcohol compound in the presence of a nitroalkane compound and a cupin-nitroaldolase.
    Type: Grant
    Filed: August 8, 2019
    Date of Patent: October 5, 2021
    Assignee: Patheon Austria GMBH & CO KG
    Inventors: Kerstin Steiner, Mandana Gruber, Romana Wiedner, Helmut Schwab
  • Patent number: 11130947
    Abstract: The present invention provides engineered phenylalanine ammonia-lyase (PAL) polypeptides and compositions thereof, as well as polynucleotides encoding the engineered phenylalanine ammonia-lyase (PAL) polypeptides.
    Type: Grant
    Filed: October 14, 2019
    Date of Patent: September 28, 2021
    Assignee: Codexis, Inc.
    Inventors: Gjalt W. Huisman, Nicholas J. Agard, Benjamin Mijts, Jonathan Vroom, Xiyun Zhang
  • Patent number: 11111484
    Abstract: The present invention provides methods, compositions and articles of manufacture useful for the prophylactic and therapeutic amelioration and treatment of gram-positive bacteria, including Streptococcus and Staphylococcus, and related conditions. The invention provides compositions and methods incorporating and utilizing Streptococcus suis derived bacteriophage lysins, particularly PlySs2 and/or PlySs1 lytic enzymes and variants thereof, including truncations thereof. Methods for treatment of humans are provided.
    Type: Grant
    Filed: December 9, 2019
    Date of Patent: September 7, 2021
    Assignee: THE ROCKEFELLER UNIVERSITY
    Inventors: Vincent A. Fischetti, Jonathan Schmitz, Daniel Gilmer, Chad Euler
  • Patent number: 11104926
    Abstract: Provided are N,N?-diacyl rhodamine compounds, which may be converted to rhodamine by porcine liver esterase (PLE) to produce a fluorescence signal. These compounds may be used, for example, as substrates in enzymatic assays or as labels in cellular imaging.
    Type: Grant
    Filed: March 26, 2019
    Date of Patent: August 31, 2021
    Assignees: Vanderbilt University, Meharry Medical College
    Inventors: Gary A. Sulikowski, Kristopher K. Abney, Susan J. Ramos-Hunter, Ian M. Romaine, Charles David Weaver
  • Patent number: 11091787
    Abstract: Methods for recombinant and enzymatic production of mogroside compounds and compositions containing mogroside compounds are provided by this invention.
    Type: Grant
    Filed: March 2, 2020
    Date of Patent: August 17, 2021
    Assignee: EVOLVA SA
    Inventors: Jens Houghton-Larsen, Katarzyna Krzystanek, Angelika Semmler, Iver Klavs Riishede Hansen, Soren Damkiaer, Yaoquan Liu, Jorgen Hansen, Sathish Kumar, Muthuswamy Panchapagesa Murali, Nina Nicoline Rasmussen
  • Patent number: 11091749
    Abstract: Compositions comprising deimmunized lysostaphin and methods of using the same, e.g., to treat microbial infection in or on a subject, are provided.
    Type: Grant
    Filed: June 5, 2019
    Date of Patent: August 17, 2021
    Assignees: TRUSTEES OF DARTMOUTH COLLEGE, STEALTH BIOLOGICS, LLC
    Inventors: Karl E. Griswold, Chris Bailey-Kellogg, Yoonjoo Choi, Kristina Blazanovic, Hongliang Zhao, Deeptak Verma
  • Patent number: 11078299
    Abstract: Isolated histidyl-tRNA synthetase splice variant polynucleotides and polypeptides having non-canonical biological activities are provided, as well as compositions and methods related thereto.
    Type: Grant
    Filed: April 7, 2020
    Date of Patent: August 3, 2021
    Assignees: aTyr Pharma, Inc., Pangu BioPharma Limited
    Inventors: Jie Zhou, Ching-Fun Lau, Zhiwen Xu, Wing-Sze Lo, Kristi Helen Piehl, Leslie Ann Greene
  • Patent number: 11072787
    Abstract: The present invention provides histidyl-tRNA synthetase and Fc region conjugate polypeptides (HRS-Fc conjugates), such as HRS-Fc fusion polypeptides, compositions comprising the same, and methods of using such conjugates and compositions for treating or diagnosing a variety of conditions. The HRS-Fc conjugates of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic and biological properties relative to corresponding, unmodified HRS polypeptides.
    Type: Grant
    Filed: April 7, 2020
    Date of Patent: July 27, 2021
    Assignee: aTyr Pharma Inc.
    Inventors: Chi-Fang Wu, Darin Lee, Jeffry D. Watkins, Kristi Piehl, Kyle P. Chiang, Marc Thomas, Minh-Ha Do, Ying Buechler, John D. Mendlein
  • Patent number: 11041181
    Abstract: The present disclosure relates to a polynucleotide having a novel promoter activity, a composition for expressing a gene comprising the polynucleotide, a microorganism comprising the gene, and a method for preparing purine nucleotides using the microorganism.
    Type: Grant
    Filed: April 8, 2019
    Date of Patent: June 22, 2021
    Assignee: CJ CHEILJEDANG CORPORATION
    Inventors: Min Ji Baek, Ji Hye Lee, So Jung Park, Jee Yeon Bae
  • Patent number: 11041002
    Abstract: The methods and systems disclose enzymes that function to import malonic acid or malonates into a cell. The enzymes increase the output of precursor molecules by enriching certain pathways in the cell. The precursor molecules can be converted to cannabinoids. The enzymes are a family of proteins which have a majority of common alignments.
    Type: Grant
    Filed: September 3, 2019
    Date of Patent: June 22, 2021
    Assignee: CB THERAPEUTICS, INC.
    Inventors: Erin Marie Scott, Jacob Michael Vogan
  • Patent number: 11041174
    Abstract: Disclosed herein are compositions for linking DNA binding domains and cleavage domains (or cleavage half-domains) to form non-naturally occurring nucleases. Also described are methods of making and using compositions comprising these linkers.
    Type: Grant
    Filed: June 7, 2019
    Date of Patent: June 22, 2021
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: David Paschon, Lei Zhang
  • Patent number: 11034967
    Abstract: The present invention provides for novel metabolic pathways to reduce or eliminate glycerol production and increase product formation. More specifically, the invention provides for a recombinant microorganism comprising a deletion of one or more native enzymes that function to produce glycerol and/or regulate glycerol synthesis and one or more native and/or heterologous enzymes that function in one or more engineered metabolic pathways to convert a carbohydrate source, such as lignocellulose, to a product, such as ethanol, wherein the one or more native and/or heterologous enzymes is activated, upregulated, or downregulated.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: June 15, 2021
    Assignee: Lallemand Hungary Liquidity Management LLC
    Inventors: Aaron Argyros, William Ryan Sillers, Trisha Barrett, Nicky Caiazza, Arthur J. Shaw, IV